Metabolic-Associated Fatty Liver Disease
Conditions
Interventions
Mixed diet pattern + exercise intervention group:Mixed dietary pattern (low-carbohydrate for 2 weeks + energy restriction for 4 weeks + low-carbohydrate for 2 weeks + energy restriction for 4 weeks) +
participants are instructed to wear heart rate monitoring devices themselves, and during concentrated time periods, brisk walk for half an hour)
low-carbohydrate diet pattern + exercise intervention group:Low-carbohydrate diet pattern (12 weeks, with carbohydrate proportion at 45%, protein at 25%, and fat at 30%) + exercise intervention group
energy-restricted balanced diet pattern + exercise intervention group:Energy balance dietary pattern (all 1200 kcal, reducing daily intake by 500 kcal compared to target, with carbohydrates accounting
pure exercise intervention group:The simple exercise intervention group (self-selected 5 days per week for 30 minutes of brisk walking during concentrated time periods at moderate target heart rate),
Sponsors
Panzhihua Central Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age between 20 and 65 years old; meets the diagnostic criteria in the 'International Expert Consensus on Metabolic-Associated Fatty Liver Disease' (based on hepatic steatosis, as determined by liver biopsy histology, imaging, or blood biomarker testing), and simultaneously satisfies one of the following three conditions: overweight/obesity, type 2 diabetes, or >=2 manifestations of metabolic dysfunction (lean or normal-weight type).
Exclusion criteria
Exclusion criteria: 1. Merge other liver disease patients; 2. Pregnant and lactating women; 3. History of Weight Loss Drug Use; 4. Those with impaired heart, lung, and kidney function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Controlled Attenuation Parameter, CAP; | — |
Secondary
| Measure | Time frame |
|---|---|
| alanine aminotransferase, ALT;aspartate aminotransferase, AST;total cholesterol, TC;low density lipoprotein cholesterol, LDL-C; | — |
Countries
China
Contacts
Public ContactZhu Xiuyun
Panzhihua Central Hospital
Outcome results
None listed